NF1 and plexiform neurofibroma: The data are consistent with lack of tovorafenib antitumor activity being reported in granulocytes/erythroids/macrophages/megakaryocytes (GEMM) models of plexiform neurofibroma harboring germline NF1-LOF mutations (29).